Protein a Resin Global Market Report 2024

The protein a resin market size has grown strongly in recent years. It will grow from $1.53 billion in 2023 to $1.67 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth observed in the historical period can be attributed to factors such as the increasing production of biopharmaceuticals, the growing adoption of monoclonal antibodies, expanding research and development activities, regulatory emphasis on the quality of biopharmaceuticals, and the rising prevalence of chronic diseases.

The protein a resin market size is expected to see strong growth in the next few years. It will grow to $2.37 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%. The anticipated growth in the forecast period can be attributed to factors such as the rising development of biosimilars, a focus on cost-efficiency in biopharmaceutical production, increased investment in bioprocessing facilities, the expansion of the biopharmaceutical market in emerging economies, and a growing demand for personalized medicine. Major trends expected in the forecast period include the adoption of single-use systems, continuous technological advancements, increased demand in emerging markets, strategic collaborations and partnerships, and a heightened focus on sustainable practices within the biopharmaceutical industry.

The anticipated increase in R&D investments within pharmaceutical companies is poised to drive the growth of the protein A resin market. Research and Development (R&D) involve the exploration and creation of new drugs, therapies, technologies, or services aimed at enhancing patient health. Protein A resin is a crucial component in chromatography assays utilized during pharmaceutical development processes. In 2022, Roche Holding AG, a Switzerland-based pharmaceutical company, set a record by spending $16.79 billion on R&D, marking a 3.7% increase from 2021. Similarly, Merck, a US-based pharmaceutical company, elevated its R&D spending by 10% in 2022, reaching $13.54 billion. Consequently, the heightened R&D investments in pharmaceutical firms are fostering the expansion of the protein A resin market.

The expected rise in healthcare expenditure is projected to propel the growth of the protein A resin market. Healthcare expenditure encompasses the total funds allocated to healthcare services, goods, and activities within a specific healthcare system or economy over a defined period. Increased healthcare spending facilitates greater investment in research and development activities related to protein A resin, fostering innovations, refining manufacturing processes, enhancing efficiency, driving advancements, improving production capabilities, ensuring product quality, and ultimately contributing to the growth and accessibility of this vital component in biopharmaceutical manufacturing. For example, in May 2023, the UK's Office for National Statistics reported a 9.4% nominal and 9.7% real increase in healthcare spending. In 2021, the UK's total healthcare cost was $367.25 billion (£280.7 billion), with pharmaceutical costs reaching $51.84 billion (£39.6 billion), and spending on preventative care rose significantly to $45.93 billion (£35.1 billion). Hence, the escalating healthcare expenditure is steering the growth of the protein A resin market.

Product innovations emerge as a prominent trend gaining momentum in the protein A resin market. Major companies in this market are introducing innovative solutions to maintain their competitive edge. For instance, in February 2021, Repligen Corporation, a US-based developer of materials for manufacturing biological drugs, collaborated with Navigo Proteins GmbH, a Germany-based biotechnology company, to launch the NGL COVID-19 Spike Protein Affinity Resin. This novel protein A resin is designed for multiple COVID-19 vaccine treatments, showcasing its unique features in the evolving landscape of the pandemic.

Major companies operating in the protein A resin market are concentrating on developing innovative products such as chromatography resins to drive revenues in their market. Chromatography resins play a crucial role in research and development, utilized for purification and analysis purposes. In September 2021, Purolite Corporation, a US-based company specializing in ion exchange resins, introduced Praesto Jetted A50 HipH and Praesto Jetted dt 18-DVB. Praesto Jetted A50 HipH is a pH-sensitive resin for purifying proteins containing Fc, while Praesto Jetted (dT)18-DVB is a styrene jetted resin for purifying mRNA structures used in gene therapy and vaccination applications. These innovative resins offer improved performance compared to existing solutions.

In September 2021, Repligen Corporation, a US-based biotechnology company, completed the acquisition of Avitide Inc. for $150 million in cash and $75 million in Repligen stocks. This strategic move enhances Repligen's protein business, particularly in the field of affinity ligand discovery, strengthening its capabilities in ligand discovery and development. Avitide Inc. is a US-based developer of protein A resin and affinity ligands.

Major companies operating in the protein a resin market report are PerkinElmer Inc., GenScript Biotech Corporation, Agilent Technologies Inc., Repligen Corporation, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Abcam plc, Novasep Holdings SAS, GE Healthcare Technologies Inc., Merck KGaA, Expedeon Ltd., Tosoh Bioscience LLC, Purolite Corporation, Kaneka Corporation, JSR Life Sciences Corporation, Agarose Beads Technologies, JNC Corporation, Danaher Corporation, Orochem Technologies Inc., Avantor Inc., Global Life Sciences Solutions USA, EMD Millipore Corp., Nippon Shokubai Co. Ltd., Bio-Works Technologies AB, Asahi Kasei Corporation, Avantor Performance Materials LLC, Life Technologies Corporation, Avacta Life Sciences Limited, Genscript Corporation, Purolite Lifesciences.

North America was the largest region in the Protein A Resin market in 2023. Europe is expected to be the fastest-growing region in the protein A resin market report during the forecast period. The regions covered in the protein a resin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the protein a resin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of protein A resins include natural protein A and recombinant protein A. Natural protein A is a high-efficiency chromatography medium produced in the bacteria Staphylococcus aureus. The matrix types involved in protein A resins are agarose-based protein A, glass/silica-based protein A, and organic polymer-based protein A. These resins find applications in various processes, including antibody purification and immunoprecipitation. Protein A resins are commonly employed by biopharmaceutical manufacturers, clinical research laboratories, and academic institutes.

The protein A resin market research report is one of a series of new reports that provides protein A resin market statistics, including protein A resin industry global market size, regional shares, competitors with a protein A resin market share, detailed protein A resin market segments, market trends, and opportunities, and any further data you may need to thrive in the protein A resin industry. This protein A resin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.